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Abstract
There is an ongoing debate concerning the risk
benefit ratio of psychopharmacologic compounds.
With respect to the benefit, recent reports and meta-
analyses note only small effect sizes with comparably
high placebo response rates in the psychiatric field.
These reports together with others lead to a wider,
general critique on psychotropic drugs in the
scientific community and in the lay press. In a
recently published article, Leucht and his colleagues
compare the efficacy of psychotropic drugs with the
efficacy of common general medicine drugs in
different indications according to results from
reviewed meta-analyses. The authors conclude that,
overall, the psychiatric drugs were generally not less
effective than most other medical drugs. This article
will highlight some of the results of this systematic
review and discuss the limitations and the impact of
this important approach on the above mentioned
debate.
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Background
Psychiatry, psychiatric patients and psychiatric medica-
tion are still highly stigmatized. Psychiatry itself often
promotes stigmatisation via close collaborations with the
pharmaceutical industry and the disregard of psy-
chotherapy, often overemphasizing the impact of psy-
chopharmacology. A different line of criticism arises
from recent meta-analyses questioning the efficacy of
psychopharmacologic compounds. Examples are meta-
analyses that have questioned the effectiveness [1] and
safety of antidepressants [2]. With respect to the effi-
cacy, the presumably high placebo effect in psychiatry
has also often led to criticisms regarding the prescrip-
tion of psychiatric drugs. These, together with other stu-
dies, have fuelled an overcritical attitude towards
psychiatry and an ongoing debate about the use of psy-
chiatric medications [3].
The British Journal of Psychiatry recently published a
systematic review, planned and conducted by a psychia-
trist who is an experienced member of the Cochrane
collaboration and familiar with the pitfalls of meta-ana-
lyses - this article is a milestone in destigmatizing psy-
chiatry and its pharmacological treatments [4].
A new approach
In the review by Stefan Leucht et al., the authors com-
pared the efficacy of psychiatric medications with gen-
eral medicine medication by comparing effect sizes of
meta-analyses [4]. For that purpose a total of 94 meta-
analyses have been reviewed, of which 48 cover general
medical medications in 20 medical diseases, and 16
meta-analyses cover psychopharmacologic compounds
for 8 psychiatric disorders. Mean differences and stan-
dardized mean differences, as well as absolute and rela-
tive risk reductions, were calculated and the
observational time of the respective trials was shown.
While there were some medical drugs with impressive
high effect sizes, overall it can be concluded that psy-
chiatric drugs generally were not less effective than
most other medical drugs [4].
For example, in patients with hepatitis C infection, the
number of patients with no detectable virus at treatment
end was increased from 1% to 38%, which corresponds
to a standardized mean difference (SMD) of 2.27. Other
impressive examples are proton pump inhibitors for the
indication of reflux oesophagitis showing an increase of
remitters from 28.3% with the placebo up to 83.2%
(SMD: 1.39).
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effective first-line, options such as aspirin for the sec-
ondary prevention of cardiovascular diseases resulting in
8.2% participants per year with cardiovascular events
taking placebo as compared to 6.7% with aspirin (SMD:
0.12). Statins for the same indication are somewhat in
between those two ends. They reduce the event rate
from 17.8% with placebo to 14.1% (SMD: 0.15). Other
drugs for multifactorial diseases, such as, for example,
metformin for the indication of diabetes, show a mortal-
ity rate of 14.6% against 21.7% with placebo (SMD:
0.27), and a mean fasting blood glucose level reduction
of 1.84 mmol/l (SMD: 0.87). The use of angiotensin
converting enzyme inhibitors in primary blood pressure
reduces the cardiovascular events and mortality from
18.1% to 14.1% (SMD: 0.11).
These data are contrasted by psychiatric medications,
such as, for example, lithium in relapse prevention for
bipolar disorder resulting in 81.4% relapses with placebo
and 36.2% with lithium maintenance treatment (SMD:
1.2). A substantial reduction of relapse rates can also be
found in schizophrenia patients with a reduction from
57% relapse with placebo to 22% with an antipsychotic
(SMD: 0.92). Less pronounced are effects that can be
seen with cholinesterase inhibitors for dementia with
16.8% of patients without a cognitive decline taking pla-
cebo compared to 24.4% with an active drug (SMD:
0.26). In between are, for example, second generation
antipsychotics or haloperidol for the indication of acute
mania in bipolar disorder increasing the response rate
from 30.8% with placebo up to 49.9% with an active
drug (SMD: 0.44). Overall, sample sizes were smaller in
psychiatric indications but still sufficient due to the
robust effect sizes. In general, larger sample sizes were
necessary in medical indications in order to find signifi-
cant differences for smaller effects.
Pitfalls and limitations of this approach
However, there are numerous limitations for this
approach, (most of which are openly discussed by the
authors themselves), which should be mentioned. For
example, the translation of dichotomous variables into
SMDs is only a rough estimate, which on the other
hand was necessary in order to get a comparable mea-
sure across the diverse outcomes. A second important
limitation is that different outcomes, such as the reduc-
tion of psychopathological symptoms assessed with rat-
ing scales and mortality outcomes are not easily
comparable. However, untreated psychiatric disorders
not only can lead to suicide but also may lead to negli-
gence of, for example, severe comorbid somatic condi-
tions, which also implies considerable health risks. In
other words, psychopharmacologic compounds may also
have effects which, according to Stefan Leucht, “could
accumulate over time”.
Another limitation of the study is the selection of the
reviewed medical conditions. It was consensus based
and not complete and this selection might have been
biased. When reviewing meta-analyses, the publication
bias must also be considered and side effects, as well as
psychotherapy, should be considered. Furthermore, effi-
cacy trials rarely allow conclusions regarding the effec-
tiveness in day-to-day practice. Thus, as the authors
truly acknowledge, this review is observational and qua-
litative by nature. Despite these limitations, this work
raises some interesting and important implications and
conclusions for both fields.
What can we learn?
From a naïve point of view one might have expected
that in psychiatry, since it covers “psychic disorders”,
the placebo effect (with its psychological component)
might be higher and, as a consequence, the resulting
true “pharmacologic” effect would be lower than in gen-
eral medicine. One could also argue that in general
medicine the pathophysiology and the mechanism of
action of an active compound are somewhat clearer
than in psychiatry and, therefore, the efficacy should be
higher. But obviously neither seems to be universally
valid. The astonishing similar efficacy of psychopharma-
cological medications and general medicine medications
r e m i n d su st h a tm a n yg e n e r a lmedical conditions are,
just like psychiatric conditions, of a “multifactorial”
nature.
Therefore, it is not a surprise that in many medical
and psychiatric conditions placebo response rates are
relatively high. This may be especially true for idiopathic
and functional medical conditions such as migraine,
neurological disorders (such as Parkinson’s disease),
autoimmune disorders and asthma [5]. In other words,
not only in psychiatry but also in a variety of common
medical conditions, the placebo effect seems to be
modulated by the fact that the intake of any drug is
inevitably embedded in a specific psychosocial context
which gives rise to distinct expectations. This raises the
question of why this context may be widely accepted
and common sense in medical conditions on the one
hand, but leads to criticism with respect to the use of
medications in psychiatry on the other. Amongst others,
one important reason is that there are different areas of
stigmatization in psychiatry. Stigmas concerning psy-
chiatric illnesses can be separated and differ from stig-
mas concerning psychopharmacology [6].
I nas u r v e yo n1 , 0 8 8h e a l t h ys u b j e c t si nG e r m a n y
from 1995, 70% of all respondents answered that medi-
cations for cardiovascular conditions are effective, while
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psychiatric conditions [7]. In the same survey, more
than 40% of the respondents feared a loss of control
with psychiatric medications, but only 10% feared the
same when taking medication for cardiovascular condi-
tions [7]. Moreover, 73% felt that high blood pressure
should be treated in the first place with medications,
but only 1% believed in the efficacy of psychotherapy in
that indication. In contrast, severe paranoia should be
treated with medication according to only 4% of the
respondents, but 64% believed that psychotherapy would
be a successful treatment [7]. Against this background,
the review by Stefan Leucht et al. is an important con-
tribution to overcoming the stigma against psychiatric
medication and in putting its efficacy into a wider
perspective.
On the other hand, it should be kept in mind that the
paper by Stefan Leucht et al. only reviews pharmacolo-
gical interventions which cover a part of all available
medical treatment options. In psychiatry, for example,
next to psychopharmacology and psychotherapy, there
are other highly effective somatic treatments available,
such as electro convulsion therapy (ECT) and transcra-
nial magnetic stimulation (TMS). In general medicine,
there are, of course, more and more minimally-invasive
interventions available complementing the pharmacolo-
gic treatments, such as percutane transluminal coronary
angioplasty (PTCA).
Conclusions
This review is remarkable in two respects. Firstly, it
gives the clinician an overview over effectsizes of diverse
pharmacological treatments for medical and psychiatric
conditions Secondly the effectsizes of psychiatric and
medical conditions are compared with each other.
Within its field it allows the clinician to align his clinical
experience with the efficacy of treatments in day-to-day
practice with the results from meta-analyses. In compar-
ison to a second and different medical field, it shows us
the limitations of pharmacological interventions in a
holistic way. It thus, also, calls for more integrating
research across the field borders. A good example of
this is major depression, which is an independent risk
factor for coronary artery disease [8], and myocardial
infarction, in turn, is a known risk factor for major
depression with a great impact on the six-month out-
come [9]. To enlarge our treatment options and
improve efficacy, we should continue to expand research
across disciplines.
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